News / Announcements 2005
 
Date Article
12 Dec 2005 Oxford BioMedica Announces Result of Extraordinary General Meeting
22 Nov 2005 Oxford BioMedica Receives Notice of Patent Allowance Extending Trovax® Protection in the United States
16 Nov 2005 Oxford BioMedica Commences Second Phase II Trial with Trovax® in Renal Cell Carcinoma
16 Nov 2005 Oxford BioMedica Announces Underwritten Institutional Placing and Open Offer and Investment by Sigma-Aldrich to Raise £30.1 Million
10 Nov 2005 Oxford BioMedica’s Innurex® Nerve Regeneration Programme Highlighted During Briefing for £30 Million Link Programme
2 Nov 2005 Oxford BioMedica Announces Progress with Registration Plan and Partnership Discussions for Trovax, and Proposed Institutional Placing and Open Offer for £20-£30 Million Alongside $5 Million Investment by Sigma-Aldrich
24 Oct 2005 Oxford BioMedica Clarifies Trovax® Strategy
24 Oct 2005

Oxford BioMedica Signs LentVector® Licensing Agreement with Fortune 500 Biopharmaceutical Company
20 Oct 2005 Oxford BioMedica and Sigma-Aldrich Enter Strategic Alliance for Commercialisation of LentiVector® Technology
19 Oct 2005 Oxford BioMedica Announces Presentation by Wyeth Pharmaceuticals of Preclinical Efficacy Data with Antibody-Targeted Therapy for Cancer
18 Oct 2005 Oxford BioMedica Announces Presentation by Clinician of Phase II Results with MetXia® in Pancreatic Cancer
17 Oct 2005 Oxford BioMedica Presents Encouraging Final Phase II Results with TroVax® in Colorectal Cancer at the International Colorectal Cancer Congress
6 Oct 2005 Oxford BioMedica Announces Encouraging Preliminary Phase II Results with TroVax® in Renal Cell Carcinoma
3 Oct 2005 Oxford BioMedica Announces Appointment of Evolution Securities as Sole Broker

20 Sep 2005

 Oxford BioMedica Plc Interim Results for the Six Months Ended 30 June 2005
7 Sep 2005 Oxford BioMedica Announces Appointment of Chief Medical Officer
5 Sep 2005 Notice of Interim Results for the Six Months Ended 30 June 2005
1 Aug 2005 Oxford BioMedica Successfully Completes Stage One of the Phase II Trial with MetXia® in Pancreatic Cancer
25 Jul 2005 Oxford BioMedica is Awarded Grant for MoNuDin® from the Motor Neurone Disease Association
4 Jul 2005 Oxford BioMedica is Granted Key LentiVector® Patents in China
17 Jun 2005 Oxford BioMedica to Chair Gene and RNAi Delivery Panel at the BIO 2005 Annual International Convention
6 Jun 2005 Oxford BioMedica Signs LentiVector® Licensing Agreement with Pfizer

3 Jun 2005 Oxford BioMedica, Viragen and the Roslin Institute Report Achievement of Avian Transgenic Milestone

3 Jun 2005 Oxford BioMedica Presents Encouraging Innurex® Preclinical Efficacy Data in Spinal Cord Injury - View Abstract 59kb

16 May 2005 Oxford BioMedica Presents Updated and Encouraging TroVax® Phase II Results in Colorectal Cancer at the 2005 ASCO Annual Meeting

12 May 2005 Oxford BioMedica to Present New TroVax® Data from Phase II Trials in Colorectal Cancer at the 2005 ASCO Annual Meeting on 15 May

10 May 2005 Oxford BioMedica Annual General Meeting 2005

9 May 2005 Oxford BioMedica Receives European Patent for TroVax® Covering 5T4 Tumour Antigen-Targeted Immunotherapy

5 May 2005 Oxford BioMedica Presents Encouraging Preclinical Efficacy Data with Retinostat® in Age-Related Macular Degeneration
29 Mar 2005 Oxford BioMedica Notification of Annual General Meeting
29 Mar 2005 Oxford BioMedica Receives Notice of Allowance for US LentiVector® Patent
21 Mar 2005 Oxford BioMedica Announces Preliminary Results for the Year Ended 31 December 2004
14 Mar 2005 Oxford BioMedica Demonstrates that Its LentiVector® Technology Is the System of Choice for RNAi Applications
10 Mar 2005 Oxford BioMedica to Present at SG Cowen Health Care Conference
4 Mar 2005 Oxford BioMedica Announces Board Appointment
4 Mar 2005 Oxford BioMedica: Notice of FY2004 Preliminary Results
2 Mar 2005 Oxford BioMedica Announces Encouraging Results from Three Phase II Trials of TroVax® in Patients with Colorectal Cancer
17 Feb 2005 Oxford BioMedica and Viragen Report Progress in Avian Transgenics Biomanufacturing
7 Feb 2005 Termination of Discussions
1 Feb 2005 Oxford BioMedica Signs LentiVector® Licensing Agreement
19 Jan 2005 Response to Share Price Movement
5 Jan 2005 Oxford BioMedica Signs LentiVector® Licensing Agreement with Biogen Idec

Website by College Hill - Life Sciences
   2008 
   Archive
   2007 
   2006 
   2005 
   2004 
   2003 
   2002 
   2001
   2000
   1999
   1998
   1997
 
Email Alerts
Enter your email address to be kept informed of news updates

Unsubscribe
Enter your email address to be removed from our mailing list